Get the Stockscreener App
4.20
1.18%
-0.05
Unicycive Therapeutics Inc stock is traded at $4.20, with a volume of 408.13K.
It is down -1.18% in the last 24 hours and down -6.04% over the past month.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
See More
Previous Close:
$4.25
Open:
$4.25
24h Volume:
408.13K
Relative Volume:
0.15
Market Cap:
$74.18M
Revenue:
-
Net Income/Loss:
$-30.54M
P/E Ratio:
-2.7097
EPS:
-1.55
Net Cash Flow:
$-18.30M
1W Performance:
-10.64%
1M Performance:
-6.04%
6M Performance:
+580.82%
1Y Performance:
+1,005%
1-Day Range:
$4.16
$4.35
1-Week Range:
$3.86
$4.79
52-Week Range:
$0.2833
$8.2457
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
Name
Unicycive Therapeutics Inc
Sector
Industry
Phone
650-384-0642
Address
4300 EL CAMINO REAL, SUITE 210, LOS ALTOS
Compare UNCY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UNCY
Unicycive Therapeutics Inc
|
4.20 | 52.09M | 0 | -30.54M | -18.30M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-25 | Initiated | Guggenheim | Buy |
| Apr-04-24 | Initiated | Piper Sandler | Overweight |
Unicycive Therapeutics Inc Stock (UNCY) Latest News
Unicycive Therapeutics Raises $16.3 Million in Stock Sale - MSN
Class Action Lawsuit Alert: Levi & Korsinsky Reminds Unicycive Therapeutics, Inc. (UNCY) Investors of October 14, 2025 Deadline - Newsfile
UNCY INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Unicycive Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire
Shareholders who lost money in shares of Unicycive - GlobeNewswire
Kaplan Fox Alerts Investors of Unicycive Therapeutics, Inc. (UNCY) to a Securities Class Action Deadline on October 14, 2025 - FinancialContent
What earnings revisions data tells us about Unicycive Therapeutics Inc.July 2025 Setups & Weekly Breakout Stock Alerts - Newser
Analyzing drawdowns of Unicycive Therapeutics Inc. with statistical tools2025 Valuation Update & Trade Opportunity Analysis Reports - Newser
Can Unicycive Therapeutics Inc. rally from current levelsJuly 2025 Selloffs & Weekly High Return Stock Forecasts - Newser
Combining machine learning predictions for Unicycive Therapeutics Inc.July 2025 Decliners & Reliable Volume Spike Trade Alerts - Newser
Using Python tools to backtest Unicycive Therapeutics Inc. strategiesJuly 2025 Recap & Accurate Buy Signal Notifications - Newser
Will Unicycive Therapeutics Inc. continue its uptrend2025 Technical Patterns & Smart Investment Allocation Insights - Newser
Using data tools to time your Unicycive Therapeutics Inc. exitWeekly Volume Report & High Yield Equity Trading Tips - Newser
Why Unicycive Therapeutics Inc. is moving todayJuly 2025 Snapshot & Reliable Entry Point Trade Alerts - Newser
Volume spikes in Unicycive Therapeutics Inc. stock – what they mean2025 Market Sentiment & Consistent Growth Equity Picks - Newser
Heatmap analysis for Unicycive Therapeutics Inc. and competitorsMarket Trend Report & Intraday High Probability Setup Alerts - Newser
Has Unicycive Therapeutics Inc. found a price floorJuly 2025 News Drivers & Daily Technical Forecast Reports - Newser
Shareholders of Unicycive Therapeutics, Inc. (UNCY): Protect Your Rights Before October 14, 2025Contact Levi & Korsinsky - ACCESS Newswire
What the charts say about Unicycive Therapeutics Inc. today2025 Geopolitical Influence & Growth Focused Entry Reports - Newser
SueWallSt With Us: Levi & Korsinsky Notifies Shareholders of Class Action Against Unicycive Therapeutics, Inc - ACCESS Newswire
Unicycive Therapeutics, Inc. (UNCY) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of October 14, 2025 Deadline - ACCESS Newswire
Unicycive Faces Class Action Over FDA Misleading Claims - TipRanks
UNCY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Unicycive Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Will Unicycive Therapeutics Inc. bounce back from current supportJuly 2025 Macro Moves & Weekly High Return Stock Forecasts - Newser
How hedge fund analytics apply to Unicycive Therapeutics Inc. stockBuy Signal & Breakout Confirmation Trade Signals - Newser
Quantitative breakdown of Unicycive Therapeutics Inc. recent movePortfolio Return Summary & Detailed Earnings Play Alerts - Newser
UNCY INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Unicycive Therapeutics faces securities class action lawsuit over public statements - Investing.com India
Levi & Korsinsky Urges Unicycive Therapeutics, Inc. (UNCY) Shareholders to Act Before Lead Plaintiff Deadline October 14, 2025 - ACCESS Newswire
October 14, 2025 Deadline: Join Class Action Lawsuit Against Unicycive Therapeutics, Inc. (UNCY)Contact Levi & Korsinsky - ACCESS Newswire
Unicycive Faces Securities Lawsuit Over Drug Claims - TipRanks
Unicycive Therapeutics says co became aware of securities class action lawsuit - MarketScreener
UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
Unicycive Therapeutics Investigation: Potential Claims and Lead Plaintiff Deadline - AInvest
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics - Business Wire
UNCY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Unicycive Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Unicycive Therapeutics faces securities class action lawsuit over false statements. - AInvest
Unicycive Therapeutics sued over alleged misleading statements and FDA compliance issues. - AInvest
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
Unicycive Therapeutics granted new U.S. patent for UNI-494 to treat chronic kidney disease - MarketScreener
Unicycive Therapeutics shares rise 1.06% premarket after receiving a new U.S. patent for UNI-494 to treat Chronic Kidney Disease. - AInvest
Unicycive Wins US Patent for Kidney Disease Drug - MarketScreener
Unicycive Therapeutics granted new U.S. patent for UNI-494 to treat CKD - TipRanks
Investor Alert: Robbins LLP Informs Investors of the Unicycive Therapeutics, Inc. Class Action - The Malaysian Reserve
Can Unicycive Therapeutics Inc. recover in the next quarterNew Guidance & Verified Swing Trading Watchlist - Newser
Unicycive Therapeutics Granted New U.S. Patent for UNI-494 to Treat Chronic Kidney Disease - The Manila Times
Unicycive Therapeutics announces issuance of patent for UNI-494 to treat CKD. - AInvest
Unicycive Therapeutics Inc Stock (UNCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):